SHR 7631
Alternative Names: SHR-7631Latest Information Update: 14 Aug 2024
At a glance
- Originator Suzhou Suncadia Biopharmaceuticals
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 24 May 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in China (IV) (NCT06381050)
- 30 Apr 2024 Preclinical trials in Solid tumours in China (IV)
- 24 Apr 2024 Suzhou Suncadia Biopharmaceuticals plans phase I trial in Solid tumours (Metastatic disease, Late-stage disease, Second-line therapy and greater) (IV) (NCT06381050)